Evolutionary Genomics, Inc.

FNAMOTCHealthcare● Active

$0.00

+$0.00(+0.00%)

Market Cap$1331

P/E Ratio—

52W High$0.45

52W Low$0.0002

Avg Volume176.8

Open$0.45

Beta-0.13

Overview

Evolutionary Genomics, Inc. (FNAM) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

FNAM · earnings · updated Jun 9, 2026

Latest Earnings

Q1 FY2023Report Date: Mar 9, 2023

EPS Actual

-$0.04

Revenue

—

Fiscal Period

Q1 FY2023

FY ends December

Report Date

Mar 9, 2023

After Market Close

FNAM reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Days Away84

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q4 FY2024	Nov 18, 2024	—	—	—	—	—	—
◌ Q3 FY2024	Aug 28, 2024	—	—	—	—	—	—
◌ Q2 FY2024	May 10, 2024	—	—	—	—	—	—
◌ Q1 FY2024	Feb 12, 2024	—	—	—	—	—	—
◌ Q4 FY2023	Nov 27, 2023	—	—	—	—	—	—
◌ Q2 FY2023	May 30, 2023	—	—	—	—	—	—
◌ Q2 FY2023	Apr 8, 2023	—	—	—	—	—	—
— Q1 FY2023	Mar 9, 2023	—	-$0.04	—	—	—	—

Q4 FY2024

Nov 18, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q3 FY2024

Aug 28, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2024

May 10, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2024

Feb 12, 2024

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2023

Nov 27, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2023

May 30, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2023

Apr 8, 2023

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2023

Mar 9, 2023

EPS Actual

-$0.04

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for FNAM.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q1 FY2023	Mar 9, 2023	—	$0.70	$0.70	+0.00%
— Q4 FY2022	Oct 21, 2022	—	$0.70	$0.70	+0.00%
— Q3 FY2022	Aug 8, 2022	—	$0.70	$0.70	+0.00%
— Q2 FY2022	May 16, 2022	—	$0.70	$0.70	+0.00%
— Q1 FY2022	Mar 21, 2022	—	$0.75	$0.75	+0.00%

Q1 FY2023+0.00%

Report Date

Mar 9, 2023

EPS Beat/Miss

—

Price Before

$0.70

Price After

$0.70

Q4 FY2022+0.00%

Report Date

Oct 21, 2022

EPS Beat/Miss

—

Price Before

$0.70

Price After

$0.70

Q3 FY2022+0.00%

Report Date

Aug 8, 2022

EPS Beat/Miss

—

Price Before

$0.70

Price After

$0.70

Q2 FY2022+0.00%

Report Date

May 16, 2022

EPS Beat/Miss

—

Price Before

$0.70

Price After

$0.70

Q1 FY2022+0.00%

Report Date

Mar 21, 2022

EPS Beat/Miss

—

Price Before

$0.75

Price After

$0.75

Beat Rate0 / 5 quarters

Largest Move+0.00% (Q1 FY2023)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

Evolutionary Genomics, Inc. (FNAM) most recently reported earnings on March 9, 2023 for Q1 FY2023, posting EPS of $-0.04 (in line with the analyst consensus of —). The next FNAM earnings date is expected around September 1, 2026.

Each quarter, investors track FNAM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FNAM revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

FNAM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

FNAM earnings · 4 questions

Evolutionary Genomics, Inc.'s next earnings report is expected around September 1, 2026. FNAM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FNAM historically reports after market close (AMC).

FNAM earnings datewhen is FNAM earningsFNAM next earnings datewhen does FNAM report earningsFNAM earnings calendar

▸ Source: FMP · Evolutionary Genomics, Inc. SEC filings · US GAAP · Evolutionary Genomics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026